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Abstract
Background: Secretion of insulin and glucagon is triggered by elevated intracellular calcium levels. Although the precise
mechanism by which the calcium signal is coupled to insulin and glucagon granule exocytosis is unclear, synaptotagmin-7
has been shown to be a positive regulator of calcium-dependent insulin and glucagon secretion, and may function as a
calcium sensor for insulin and glucagon granule exocytosis. Deletion of synaptotagmin-7 leads to impaired glucose-
stimulated insulin secretion and nearly abolished Ca
2+-dependent glucagon secretion in mice. Under non-stressed resting
state, however, synaptotagmin-7 KO mice exhibit normal insulin level but severely reduced glucagon level.
Methodology/Principal Findings: We studied energy expenditure and metabolism in synaptotagmin-7 KO and control
mice using indirect calorimetry and biochemical techniques. Synaptotagmin-7 KO mice had lower body weight and body fat
content, and exhibited higher oxygen consumption and basal metabolic rate. Respiratory exchange ratio (RER) was lower in
synaptotagmin-7 KO mice, suggesting an increased use of lipid in their energy production. Consistent with lower RER, gene
expression profiles suggest enhanced lipolysis and increased capacity for fatty acid transport and oxidation in
synaptotagmin-7 KO mice. Furthermore, expression of uncoupling protein 3 (UCP3) in skeletal muscle was approximately
doubled in the KO mice compared with control mice.
Conclusions: These results show that the lean phenotype in synaptotagmin-7 KO mice was mostly attributed to increased
lipolysis and energy expenditure, and suggest that reduced glucagon level may have broad influence on the overall
metabolism in the mouse model.
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Introduction
Glucose homeostasis is tightly controlled by two counter-acting
hormones from the pancreas: insulin from beta-cells and glucagon
from alpha-cells. Insulin promotes glucose clearance from the
blood when blood glucose level is high, while glucagon restores
normal blood glucose level during hypoglycemia by stimulating
gluconeogenesis and glycogenolysis. The commonly accepted
model attributes the development of type 2 diabetes (T2D) to
relative insulin deficiency, which results from peripheral insulin
resistance, and reduced insulin release due to defective insulin
secretion and diminished beta cell mass [1]. Although much less
mentioned, dysregulated glucagon secretion is another key factor
that promotes hyperglycemia and diabetes development: loss of
glucose inhibition of glucagon secretion leads to increased glucose
production from the liver even in the presence of hyperglycemia
[2].
Secretion of endocrine hormones, such as insulin and glucagon,
is a highly regulated process and triggered by elevated intracellular
calcium levels [3]. In the case of insulin, the increased calcium
level is the result of a series of metabolic and membrane events
that include increased ATP production, closure of ATP-sensitive
potassium channels, membrane depolarization and opening of
voltage-gated calcium channels [4]. The events preceding
glucagon secretion are not as well defined, although it appears
that ATP-sensitive potassium channels and voltage-gated calcium
channels are also involved [5]. Another common feature between
insulin and glucagon secretion is that they both require a calcium-
binding protein, synaptotagmin-7, as the calcium sensor for insulin
and glucagon granule exocytosis [3,4,6].
Synaptotagmin-7 belongs to a type-1 membrane protein family
of more than 16 members [3,7]. Synaptotagmins are characterized
by an N-terminal transmembrane domain, a variable linker and
two C-terminal C2 domains [8]. The C2 domains are the
functional units of synaptotagmins, forming the basis for the
function of synaptotagmins as calcium sensors in the regulation of
exocytosis [3]. Deletion of synaptotagmin-7 in mice results in
impaired insulin secretion when the mice are challenged by high
glucose injection [4], and nearly abolished glucagon release at low
blood glucose levels, such as when induced by insulin injection [6].
While the treatment and management of hyperglycemia
especially in T2D has always been based on insulin response,
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presents a potential approach to the maintenance of normal
glucose levels. Various pharmacological and genetic approaches
have been used to evaluate the glycemic advantage of reduced
glucagon production or signalling: (i) blocking glucagon signalling
by targeted glucagon receptor gene deletion [9,10,11]; (ii) removal
of endogenous glucagon using high affinity glucagon-neutralizing
antibodies [12,13,14]; (iii) treatment with glucagon receptor anti-
sense oligonucleotide [15,16] or glucagon receptor antagonists
[17,18,19,20]; (iv) suppression of glucagon production via
pancreas-specific ablation of the alpha-cell transcription factor,
Arx, which results in a complete loss of the glucagon producing
alpha-cells [21]. These studies collectively confirmed that
disruption of glucagon production or signalling leads to an
improvement in glucose metabolism in the animal models tested.
Consistent with the notion, our recent study showed that in the
absence of dysregulated glucagon secretion, the combination of
defective insulin secretion and peripheral insulin resistance was not
sufficient to induce hyperglycemia in synaptotagmin-7 KO mice
[1]. Despite impaired calcium-dependent insulin and glucagon
granule exocytosis, synaptotagmin-7 KO mice maintain normal
resting insulin level, but significantly reduced resting glucagon
level [4,6]. Furthermore, synaptotagmin-7 KO mice have lower
body weight and body fat content [4]. In this study, we
investigated the energy balance and regulation in the KO mice.
Materials and Methods
Ethics statement
All animal experiments in this study were conducted in
accordance with the guidelines for animal care and use established
by the Institutional Animal Care and Use Committee of the
Agency for Science, Technology and Research (A*STAR)
Biomedical Science Institutes in Singapore. The approved
protocol numbers for the current study were IACUC #080351
and #090428.
Animal welfare
Synaptotagmin-7 knockout (KO) mice were generated as
previously described [22]. Only male mice were used in this
study, and they were bred and housed in our animal facility. They
were maintained at 2461uC on a 12 h/ h light/dark cycle (7:00–
19:00 h), and allowed free access to water and standard rodent
chow (Harlan 2018 Teklad Global 18% Protein Rodent Diet).
Body composition and core body temperature
measurements
Age-matched littermates of synaptotagmin-7 KO and control
mice were weighed, and their body composition was measured at
24 weeks of age by using an EchoMRI-100 (Echo Medical
Systems) essentially as previously described [4]. Mice were
anesthetised by using isoflurane before measurement of rectal
temperature.
Indirect calorimetry
Oxygen consumption (VO2), carbon dioxide production
(VCO2), respiratory exchange ratio (RER), physical activity, and
food intake were simultaneously measured for each mouse after a
1-day acclimatization period by using the Oxymax/Comprehen-
sive Lab Animal Monitoring System (Columbus Instruments,
Ohio) as previously described [23]. All oxygen consumption
measurements were normalized to lean mass (ml/hour/kg lean
mass) since lean tissues contribute more to the total energy
expenditure compared to fat mass [24]. RER, a measure of
metabolism substrate choice (carbohydrate or fat), was calculated
as the ratio between VCO2 and VO2. All data collected were
averaged over a monitoring period of 6 days.
Plasma hormone and analyte measurements
Blood samples were collected from tail vein for glucose
measurements by using Accu-Chek Advantage glucometer
(Roche). Plasma samples were prepared by blood centrifugation
at 8,000 x g for 5 min at 4uC. Mouse Insulin ELISA Assay
(Mercodia), Glucagon RIA (Millipore), Mouse Leptin ELISA
(Millipore) were used for plasma insulin, glucagon, and leptin
measurements, respectively. Non-esterified fatty acids (NEFA)
were measured with a Wako kit. Triglyceride levels were
determined in blood with Accutrend GCT System (Roche).
Tissue analysis of ATP and lipid content
Mice were killed by cervical dislocation and their hind limbs
were snap-frozen in liquid nitrogen within 1 second. Gastrocne-
mius muscle was dissected free of visible fat and connective tissues
on a metal plate that was cooled by liquid nitrogen. Muscle
samples were then homogenised in lysis buffer (supplied in ATP
Bioluminescence Assay Kit HS II, Roche). After centrifugation at
16,000 x g for 10 min at 4uC, 50 ml of supernatant was assayed for
ATP by using ATP Bioluminescence Assay Kit HS II (Roche).
Extraction of lipid content in skeletal muscle was performed as
previously described [25]. Briefly, skeletal muscle tissue was
homogenized with chloroform/methanol (2:1) at sample/solvent
ratio of 1:5, and then re-homogenized with 1 part chloroform.
One part distilled H2O was then added and the homogenate was
vortexed before centrifugation at 350 x g to separate the aqueous
phase from the organic phase. The lower organic phase was
carefully recovered for triglyceride and glycerol content analysis by
using Serum Triglyceride Determination Kit (Sigma).
Mitochondrial isolation from skeletal muscle
Mitochondrial isolations were performed on groups of synapto-
tagmin-7 KO and control mice at 24 weeks of age. Mice were killed
by cervical dislocation. Skeletal muscle was rapidly dissected from
both hind limbs, cleaned of fat and connective tissues, and collected
in ice-cold medium comprising 100 mM KCl, 50 mM Tris/HCl,
and 2 mM EGTA (pH 7.4 at 4uC). Mitochondria from skeletal
muscle were isolated essentially as previously described [26], but
with defatted BSA. Mitochondrial protein concentration was
determined by the Bradford method, with BSA as the standard.
Western blotting
Samples of mitochondria or tissue lysate were solubilized and
resolved on 10% or 12.5% SDS/PAGE gel. Proteins were blotted
onto PVDF membrane and probed using the following antibodies:
UCP1, CPT1 (Santa Cruz Biotechnology), UCP3 (Abcam), HSL,
pHSL (Cell Signaling), and beta-tubulin (Sigma).
Statistical analysis
Data are presented as means 6SEM. Comparisons of data were
made by using two-tailed Student’s t-test or ANOVA followed by
Dunnett’s post hoc test. Statistical significance is displayed as
*p,0.05 or **p,0.01.
Results
Higher metabolic rate in synaptotagmin-7 KO mice
Although deletion of synaptotagmin-7 results in 40–50%
reduction of insulin secretion and nearly abolished glucagon
Glucagon Deficiency and Energy Metabolism
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under non-stressed conditions. One distinctive phenotype was that
synaptotagmin-7 KO mice exhibited lower body weight through-
out the monitoring period from 5 to 24 weeks when compared
with the control mice (Figure 1A).
Body composition analysis by MRI revealed lower total body fat
in the 24-week old synaptotagmin-7 KO mice compared to the
control mice (Figure 1B). The proportion of body mass in fat was
also significantly lower in the synaptotagmin-7 KO mice
(Figure 1C). No significant difference in lean body mass was
observed (Figure 1D-E). Although there were no apparent
abnormalities in adipose tissue, adipocytes from synaptotagmin-7
KO mice appeared to be slightly smaller (Figure S1). These results
indicate that the lower body weight of the synaptotagmin-7 KO
mice could be attributed to their lower fat content.
To test whether the lower body weight phenotype in
synaptotagmin-7 KO mice was due to reduced food intake and/
or increased energy expenditure, we performed indirect calorim-
etry on synaptotagmin-7 KO and control mice. Food intake, either
in absolute amount or when normalized to body weight, showed
no difference between the two genotypes (3.7960.15 g/day, N=9
for synaptotagmin-7 KO mice; 3.6760.25 g/day, N=10 for
control mice). We then tested energy expenditure in synaptotag-
min-7 KO and control mice. Oxygen consumption during the day
and night periods was higher in the synaptotagmin-7 KO mice
(Figure 2A). Locomotor activity was indistinguishable between
control (56,16466,263 counts per day, N=9) and synaptotagmin-
7 KO mice (63,88366,008 counts per day, N=10). Furthermore,
basal metabolic rate (based on the rate of resting VO2) was
approximately 27% higher in the synaptotagmin-7 KO mice
(Figure 2B). A similar trend of higher carbon dioxide production
(VCO2) was also observed in the synaptotagmin-7 KO mice (data
not shown). These data show that the synaptotagmin-7 KO mice
had increased whole body metabolism. During the night period
when mice are active, synaptotagmin-7 KO mice maintained
lower RER than the control mice (Figure 2C and 2D), suggesting
that the synaptotagmin-7 KO mice consumed a higher percentage
of fat in their energy production than control mice.
Enhanced lipolysis in synaptotagmin-7 KO mice
Considering that synaptotagmin-7 KO mice consumed more fat
as fuel than the control mice, we tested whether synaptotagmin-7
KO mice had increased lipolysis and fat oxidation. Hormone-
sensitive lipase (HSL) catalyses the hydrolysis of triacylglycerol, the
rate-limiting step in lipolysis, and is the key enzyme in the
regulation of lipid stores. Several mechanisms are known to
regulate the activity of HSL, one of which is via the reversible
phosphorylation of HSL by protein kinases [27]. HSL activity is
acutely stimulated when protein kinase A (PKA) phosphorylates
HSL at Ser563, Ser659 and Ser660 [28,29]. Densitometric
analysis of pHSL (Ser660) revealed that the activity of HSL per
unit of adipose tissue isolated from synaptotagmin-7 KO mice was
Figure 1. Reduced body weight and body fat mass in synaptotagmin-7 KO mice. (A) Body weights of synaptotagmin-7 KO (Syt7
-/-) and
control (Ctrl.) mice at 5, 14, and 24 weeks of age. N=8–32 per group. (B, C) Fat mass (B) and proportion of body fat (C) in synaptotagmin-7 KO and
control mice at 24 weeks of age. (D, E) Lean mass (D) and proportion of body lean (E) in synaptotagmin-7 KO and control mice at 24 weeks of age. All
data are expressed as means 6 SEM. N=24–32 per group. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0026671.g001
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synaptotagmin-7 KO mice.
Enhanced lipolysis is usually accompanied by increased
plasma triglycerides (TG) and free fatty acids (FFA) levels.
However, we found reduced TG and FFA levels in synapto-
tagmin-7 KO mice at resting state (Table 1). This suggests
increased uptake and/or oxidation of fatty acids in muscle cells,
as skeletal muscle is a major site of fatty acid oxidation [30].
Carnitine palmitoyltransferase I (CPT I) is the principal
modulator of fatty acid oxidation (beta-oxidation) since it
catalyses the transport of fatty acyl-CoA across the mitochon-
drial membrane, and thus controls the fatty acid flux through
beta-oxidation [30]. Over-expression of CPT I protein alone has
been demonstrated to increase fatty acid oxidation in both
isolated mitochondria and intact skeletal muscle [31]. So we
examined the level of CPT I expression in skeletal muscle
mitochondria isolated from both groups of mice as an indirect
gauge of fatty acid oxidation. CPT I protein level was almost 3-
fold higher in the synaptotagmin-7 KO mice than in the control
mice (Figure 3B), supporting the notion that fatty acid oxidation
was higher in synaptotagmin-7 KO mice.
Intramuscular TG and glycerol content represents the balance
of fat accumulation and oxidation in the muscle. We found that
synaptotagmin-7 KO mice showed reduced TG and glycerol in
muscle, consistent with increased fat combustion (Figure 3C and
3D). Lipolysis yields more ATP than carbohydrate catabolism and
increased usage of fat in energy production may be reflected by
ATP content in muscle. Synaptotagmin-7 KO mice had higher
ATP level than control mice (46.264.9 versus 34.060.3 nmol/mg
protein, synaptotagmin-7 KO and control, N=7–8 per group;
P,0.05). This is in agreement with the hypothesis that
synaptotagmin-7 KO mice consumed a higher percentage of fat
in energy production based on indirect calorimetry analysis.
Consistent with higher energy production, the core body
temperature was higher in synaptotagmin-7 KO mice than the
control group (38.060.2 versus 37.460.2uC, synaptotagmin-7 KO
and control, N=10–12 per group; P,0.05). To test whether the
increased temperature was associated with inflammation, we
measured several pro-inflammatory cytokines in both groups of
mice, including IL1-a, IL1-b and IL-6, but found no difference
(data not shown).
Upregulated expression of UCP3 in skeletal muscle
mitochondria of synaptotagmin-7 KO mice
The observed lower body weight and body fat, coupled with
increased metabolic rate and core body temperature, suggest
increased uncoupling protein (UCP) activity. We examined the
expression levels of UCP1 and UCP3. UCP1 is exclusively found
in brown adipose tissue and is known to mediate facultative
thermogenesis in hibernating mammals and rodents [32]. UCP1
expression in the brown adipose tissue of synaptotagmin-7 KO
mice was similar to that of the control mice (Figure 4A), whereas
the expression of UCP3 was significantly elevated in the skeletal
muscle of synaptotagmin-7 KO mice (Figure 4B). In adult mice,
synaptotagmin-7 expression was mostly restricted to brain and
endocrine cells [33], and was not detected in skeletal muscle
(Figure 4C). Thus, it is unlikely that the up-regulation of UCP3
was a direct effect of synaptotagmin-7 deletion.
Figure 2. Enhanced metabolism in synaptotagmin-7 KO mice. (A) Rate of daily oxygen consumption for synaptotagmin-7 KO (Syt7
-/-) and
control (Ctrl.) mice during the day, night and whole-day periods. (B) Basal metabolic rate as measured in terms of oxygen consumption (ml/hour/kg
lean mass) for synaptotagmin-7 KO and control mice. (C) RER of synaptotagmin-7 KO and control mice over a 24-hour monitoring period. (D) RER
calculated from data in (C) during day (0700–1900 h) and night (1900–0700 h). All data are presented as means 6 SEM. N=9–10 per genotype.
*, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0026671.g002
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Glucagon restores normal blood glucose levels by increasing
hepatic glucose production and disruption of glucagon signalling
results in hypoglycemia [9,10,12,13,14,15,16,17,18,19,20]. In
synaptotagmin-7 KO mice, calcium-dependent glucagon secretion
was nearly abolished [6], and lower blood glucose was observed
when synaptotagmin-7 KO mice were subjected to prolonged
starving [1]. On the other hand, dysregulated glucagon secretion
and enhanced glucagon signalling may directly promote hyper-
glycemia and diabetes [1,2,34]. We recently showed that without
dysregulated glucagon secretion, the combination of defective
insulin secretion and peripheral insulin resistance was not sufficient
to induce hyperglycemia in synaptotagmin-7 KO mice [1]. In light
of renewed interest in targeting glucagon signalling for the
prevention and treatment of hyperglycemia and diabetes, it is
important to understand how absolute glucagon deficiency and
impaired glucagon secretion affect energy homeostasis.
Although deletion of synaptotagmin-7 results in impaired
insulin secretion in response to high glucose challenge, synapto-
tagmin-7 KO mice exhibit normal resting insulin levels under non-
stressed conditions when the mice have free access to feed ([4] and
data not shown). In contrast to insulin, glucagon levels in
synaptotagmin-7 KO mice are always lower, and do not increase
after fasting (Table 1) [4,6]. Therefore, synaptotagmin-7 KO mice
may be used to understand the metabolic consequences of
glucagon deficiency. Consistent with previous observations,
synaptotagmin-7 KO mice have lower body weight and are
leaner than the control mice [4] (Figure 1). Here we show that the
lower body weight was not due to reduced food intake, but rather
increased energy expenditure in synaptotagmin-7 KO mice as
indicated by the higher oxygen consumption rate and higher basal
Figure 3. Enhanced lipolytic enzyme and reduced muscle TG content in synaptotagmin-7 KO mice. (A, B) Representative immunoblots
and quantification of protein levels of phopho-HSL (pHSL) from fat pads (A), and CPT1 from skeletal muscle mitochondria (B) of 20–24 week old
synaptotagmin-7 KO and littermate control mice. Densitometric quantification for each protein was normalized against beta-tubulin from 3-5
independent pairs of synaptotagmin-7 KO and control mouse samples. (C) Triglyceride (TG) and (D) glycerol content from muscle samples. N=4 per
genotype. Data are presented as means 6 SEM. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0026671.g003
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indicates that the higher energy expenditure could be largely
attributedto increased use of fatas fuel inthese mice(Figure 2C and
2D), as synaptotagmin-7 KO mice show upregulation of lipolytic
enzyme (Figure 3A) and increased capacity for fatty acid transport
and oxidation (Figure 3B-D). In addition, synaptotagmin-7 KO
mice exhibit non-inflammatory hyperthermia due to mitochondrial
uncoupling, possibly through increased UCP3 expression
(Figure 4B), or increased fatty acid oxidation [35]. These metabolic
alterations are contributing factors to the observed lean phenotype
in the synaptotagmin-7 KO mice.
The mechanisms by which energy expenditure was increased
through lipolysis are unclear. Our findings that synaptotagmin-7
KO mice have reduced lipid accumulation in skeletal muscle and
low circulating levels of TG and FFA suggest that synaptotag-
min-7 KO mice have developed compensatory mechanisms for
the persistent low glucagon levels, for example by increasing
lipolytic enzyme levels. Consistent with increased fatty acid
oxidation, mitochondria isolated from skeletal muscles of
synaptotagmin-7 KO mice showed increased UCP3 expression
(Figure 4B). The link between increased UCP3 expression and
enhanced fatty acid oxidation was also reported previously: (i)
UCP3 expression was increased in animal and human subjects
undergoing metabolic states with high fatty acid oxidation
(fasting [36], acute bouts of exercise [37,38], and high fat feeding
[39]); (ii) increased fatty acid oxidation was observed in UCP3
over-expression mouse studies [40] or other over-expression
systems [41]. The exact role of UCP3 in fatty acid oxidation is
still unclear, but one proposed role for UCP3 is in the export of
fatty acid anions thus permitting continuous rapid fatty acid
oxidation during an oversupply [42]. It is also unclear how the
increased lipolysis occurred in the synaptotagmin-7 KO mice.
Sympathetic nerve activity and catecholamines are known
triggers of increased lipolysis and UCP3 expression [43,44].
Although deletion of synaptotagmin-7 impairs secretory granule
exocytosis in chromaffin cells [45], we did not observe significant
differences in epinephrine, norepinephrine or dopamine levels
between synaptotagmin-7 KO and control mice (data not
shown).
In summary, the present study reveals altered metabolic
responses in synaptotagmin-7 KO mice, including increased
lipolysis, fatty acid transport and oxidation, and the increased
use of fat as fuel. The increased fatty acid oxidation or utilization
observed in the present study provides a plausible explanation for
the lean phenotype in the synaptotagmin-7 KO mice. This study,
however, does not indicate that changes to metabolism are a direct
effect of synaptotagmin-7 deletion but possibly the result of
systemic effect of glucagon deficiency on the overall animal
metabolism. Our study corroborates certain beneficial effects of
reduced glucagon signalling, and supports its therapeutic potential
in the prevention and treatment of diabetes and other metabolic-
related diseases.
Table 1. Plasma or serum analytes of synaptotagmin-7 KO
and control mice.
Control
Synaptotagmin-7
KO Statistics
Mean ± SEM No. Mean ± SEM No.
Glucose (mM)
Fed 8.760.3 13 8.860.3 13 NS
Fasting 5.560.2 13 5.160.2 13 NS
Insulin (ng/ml)
Fed 4.0860.46 13 3.3160.28 13 NS
Fasting 1.3560.08 13 1.0260.09 13 P,0.05
Glucagon (pM)
Fed 83.069.2 13 51.665.3 13 P,0.01
Fasting 116.566.9 12 53.766. 7 12 P,0.001
Lipids
Cholesterol (mM) 4.1360.02 7 4.1060.02 6 NS
Triglycerides (mM) 1.8060.19 7 1.2560.07 6 P,0.05
Free fatty acids (mM) 253.1624.8 13 170.0620.7 13 P,0.01
doi:10.1371/journal.pone.0026671.t001
Figure 4. Increased UCP3 expression in the skeletal muscle mitochondria of synaptotagmin-7 KO mice. (A, B) Representative
immunoblots of UCP1 from brown adipose tissue (A) and UCP3 from skeletal muscle (B) of 20–24 week old synaptotagmin-7 KO and control mice.
Relative densitometric quantification was normalized against beta-tubulin. Each set of samples was from 3–5 mice. (C) Synaptotagmin-7 (arrows) was
not detected in skeletal muscle. Data are presented as means 6 SEM. **, P,0.01.
doi:10.1371/journal.pone.0026671.g004
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Figure S1 Comparison of white adipose tissue from
synaptotagmin-7 KO and control mice.H&E staining of
white adipose tissue sections from synaptotagmin-7 KO (Syt7
-/-)
and control (Ctrl.) mice. Images were obtained on a Nikon
inverted microscope. Scale bar =200 mm.
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